Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, noviembre 19
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
VivoSim Labs Inc
VIVS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.1859
0.0659
54.92%
Últ. Act.: Nov 19, 9:49 AM
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
VivoSim Labs Financials
VivoSim Labs (VIVS) financial statements — income, revenue, gross margin and key metrics.
PRO
¿Por qué se mueve?:
VivoSim Labs shares are trading higher after the company announced it signe...
Ganancias:
Los beneficios de Q2 2027 se publicaron el jue nov 12th, después del cierre del mercado
Earnings & Guidance News
S&P 500 Gains 1%; US Initial Jobless Claims Edge Higher
U.S. stocks climbed, led by tech: Nasdaq +1.92%, S&P 500 +1.09%. Jobless claims rose to 203,000; oil gained while gold fell.
Avi Kapoor
PRO
VivoSim Labs Signs Seven-Figure Agreement With Top-10 Global Pharma Company; Now Expects To Exceed 500%+ FY27 Revenue Growth Guidance
Benzinga Newsdesk
PRO
VivoSim Labs Q2 EPS $(0.03) Up From $(0.98) YoY, Sales $51.000K Up From $28.000K YoY
VivoSim Labs (NASDAQ:VIVS) reported quarterly losses of $(0.03) per share. This is a 96.94 percent increase over losses of $(0.98) per share from the same period last year. The company reported $51.000 thousand in
Benzinga Newsdesk
PRO
VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue
Benzinga Newsdesk
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
Avi Kapoor
PRO
VivoSim Labs Q1 EPS $(1.14) Up From $(2.76) YoY, Sales $37.000K Down From $39.000K YoY
VivoSim Labs (NASDAQ:VIVS) reported quarterly losses of $(1.14) per share. This is a 58.7 percent increase over losses of $(2.76) per share from the same period last year. The company reported $37.000 thousand in sales
Benzinga Newsdesk